Skip to main content
Toggle navigation
Login
Search
Home
Tweets by IDWeek 2022
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Favorite
Like
Tweet this
Print
Phoebe Nakanwagi, Master’s in Biostatistics
GSK, Belgium
Disclosure(s): GlaxoSmithKline Biologicals SA: Employee
Poster(s):
96 - A Candidate Respiratory Syncytial Virus (RSV) Prefusion F Protein Investigational Vaccine (RSVPreF3 OA) Is Immunogenic when Administered in Adults ≥ 60 Years of Age: Results at 6 Months after Vaccination
Thursday, October 20, 2022
12:15 PM – 1:30 PM
US ET
119 - Safety and Reactogenicity of an Investigational Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine for Adults ≥ 60 Years of Age (RSVPreF3 OA): an Interim Analysis at 6 Months after Vaccination
Thursday, October 20, 2022
12:15 PM – 1:30 PM
US ET
.png)
.png)